PropertyValue
?:abstract
  • AstraZeneca has contracted with Lonza to manufacture its antibody to prevent and treat COVID-19 A combination of two long-acting antibodies, AZD7442 is in Phase 1 clinical trials, and AstraZeneca anticipates starting Phase 3 trials by year’s end Under the contract, Lonza, a Swiss pharmaceutical services firm, will produce the antibodies in a new facility at its Portsmouth, New Hampshire, biologics complex in the first half of 2021 [ ]
is ?:annotates of
?:creator
?:journal
  • C&EN_Global_Enterprise
?:license
  • unk
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:source
  • WHO
?:title
  • AstraZeneca picks Lonza for COVID drug
?:type
?:who_covidence_id
  • #926237
?:year
  • 2020

Metadata

Anon_0  
expand all